Eiger BioPharmaceuticals, Inc.: key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2023)
- $15.8M
- Net Income/Loss (FY2023)
- -$75.0M
- Total Assets (FY2023)
- $38.8M
- Total Equity (FY2023)
- -$14.5M
- Cash Flows from Operating Activities (FY2023)
- -$74.5M
Source: Eiger BioPharmaceuticals, Inc. 10-K filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
